| Name | Title | Contact Details |
|---|
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.
The BridgeWay Hospital, located in Central Arkansas, offers an innovative recovery experience at the foothills of the Ouachita Mountains. Here, we offer a continuum of services designed to help children, adolescents, adults and seniors who are experien...
Lafayette Drug Company, is a Lafayette, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anda Inc is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.